Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Real-world Evidence of Inebilizumab in IgG4-RD (REDUCE)

19. november 2026 opdateret af: Wen Zhang, Peking Union Medical College Hospital

Real-world Evidence of Inebilizumab in Decreasing Corticosteroid Use and Improving Clinical Efficacy in IgG4-RD

The goal of this observational study is to observe the efficacy and safety of inebilizumab in the treatment of IgG4-related disease. The main question it aims to answer the optimal steroid-sparing regimen for patients with IgG4-RD in clinical practice.

This study will enroll all patients with IgG4-RD treated with inebilizumab. Enrolled patients will receive different treatment regimens according to disease severity and whether they are taking other immunosuppressive agents.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Detaljeret beskrivelse

All enrolled patients will be categorized into four subtypes based on disease severity and concomitant use of other immunosuppressive agents:

Group1 Treatment-naive active disease treated with inebilizumab monotherapy group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that the disease is suitable for inebilizumab monotherapy; Group2 Treatment-naive active disease treated with short-course corticosteroids plus inebilizumab group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that short-course corticosteroids are required in combination; Group3 Stable disease continued-treatment group: patients with stable disease control on long-term corticosteroids or corticosteroids plus conventional immunosuppressants, who are at high risk of relapse after discontinuation and are willing to switch to a steroid-free inebilizumab treatment regimen; Group4 Relapsed/refractory patient group: patients who experience relapse while receiving corticosteroids or corticosteroids combined with immunosuppressants.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

100

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

All IgG4-related disease patients treated with inebilizumab.

Beskrivelse

Inclusion Criteria:

  1. Aged ≥18 years old;
  2. Meet the 2019 ACR/EULAR classification criteria or the 2020 Japanese diagnostic criteria for IgG4-RD;
  3. Plan to receive treatment with inebilizumab;
  4. Signed informed consent form.

Exclusion Criteria:

  1. Pregnant or lactating female patients;
  2. Participation in other interventional studies within 30 days prior to screening, or exposure to investigational products within 5 half-lives before enrollment, or planned participation in other interventional studies during the trial period;
  3. Patients with contraindications to inebilizumab treatment;
  4. Any other conditions deemed inappropriate for enrollment by the investigator.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: CROSS_SECTIONAL

Kohorter og interventioner

Gruppe / kohorte
Patients with IgG4-RD treated with inebilizumab

Patients with IgG4-RD receiving inebilizumab in the real-world setting

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Relapse rate
Tidsramme: One year after inebilizumab treatment

Flare of IgG4-RD is defined as the reappearance of previous symptoms or signs of IgG4-RD or the appearance of new symptoms or signs attributed to IgG4-RD, based on clinical assessment, laboratory tests, and/or imaging, and reflected by an increase in the IgG4-RD Responder Index

One year after inebilizumab treatment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of subjects achieving flare-free and treatment-free complete remission
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment

Flare-free and treatment-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity

Three Months, six months and twelve months after inebilizumab treatment
Proportion of subjects achieving flare-free and glucocorticoid-free complete remission
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment

Flare-free and glucocorticoid-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity

Three Months, six months and twelve months after inebilizumab treatment
Remission rate after inebilizumab treatment
Tidsramme: Six months and twelve months after inebilizumab treatment

The investigator determined that there was no evidence of disease activity at the visit

Six months and twelve months after inebilizumab treatment
IgG4-RD Responder Index (IgG4-RD RI) after inebilizumab treatment
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment

Measured by IgG4-RD Responder Index

Three Months, six months and twelve months after inebilizumab treatment
IgG4-RD Damage Index (IgG4-RD DI) after inebilizumab treatment
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment

Measured by IgG4-RD Damage Index

Three Months, six months and twelve months after inebilizumab treatment
Changes in serum IgG4 levels from baseline after inebilizumab treatment
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment

Laboratory markers

Three Months, six months and twelve months after inebilizumab treatment
Changes in serum B-cell levels from baseline after inebilizumab treatment
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment

Laboratory markers

Three Months, six months and twelve months after inebilizumab treatment
Total amount of glucocorticoids during inebilizumab administration
Tidsramme: One year after inebilizumab treatment

Total amount of glucocorticoids calculated as the cumulative glucocorticoid dose (in milligrams) taken for the purpose of IgG4-RD disease control. This measure accounted for all glucocorticoids treatments administered to participants to manage disease activity throughout the study period.

One year after inebilizumab treatment
Improvement in patients' quality of life during inebilizumab administration
Tidsramme: One year after inebilizumab treatment

Quality of life measured by the EQ-5D-5L questionnaire

One year after inebilizumab treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. januar 2027

Primær færdiggørelse (Anslået)

1. december 2028

Studieafslutning (Anslået)

1. december 2029

Datoer for studieregistrering

Først indsendt

8. november 2026

Først indsendt, der opfyldte QC-kriterier

19. november 2026

Først opslået (Faktiske)

20. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

19. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • I-26PJ0909

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

IPD will not be shared with other researchers. Data may be made available to regulatory authorities, trial monitors, auditors, and ethics committees as required for trial oversight, monitoring, audit, and verification.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .